Bellevue’s BB Biotech builds “bibi” AI operating system to support biotech stock-picking process

• Bellevue Group management outlined a plan to embed AI deeper into BB Biotech’s investment process without changing decision-making fundamentals.
• New proprietary “operating system,” dubbed “bibi,” aims to unify fragmented research, models, decisions, outcomes into a persistent, traceable knowledge layer.
• System designed to pre-model clinical trial scenarios, then flag assumption shifts versus trial design once data releases.
• Investment team retains final capital-allocation calls; AI positioned for computation, scenario generation, thesis challenges, not judgment.
• Competitive edge framed as accumulated context, reasoning, decision records rather than reliance on any single AI model.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bellevue Group AG published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.